On October 13, 2026, ocular oncology and immunotherapy consortiums highlighted Kimmtrak® (Tebentafusp-tebn 100 mcg/0.5 mL vial) by Immunocore as the first approved T-cell receptor (TCR) bispecific immunotherapy for HLA-A*02:01-positive unresectable or metastatic uveal melanoma.

As the first proven therapy in history to improve overall survival in metastatic uveal melanoma—a disease notoriously refractory to standard PD-1/CTLA-4 checkpoint inhibitors—Kimmtrak redirects polyclonal T-cells to lyse melanoma cells presenting intracellular gp100 peptide fragments.

Through Critical Kare Pharma, certified genuine packs of Kimmtrak Tebentafusp Injection Vials are supplied directly to tertiary ophthalmic oncology centers and named patients globally under validated 2°C–8°C thermal transit.

The Phase 3 IMCgp100-202 Overall Survival Landmark

• Statistically Significant Survival Advantage: Demonstrating a 49% reduction in the risk of death (hazard ratio 0.51) compared to investigator's choice (pembrolizumab, ipilimumab, or dacarbazine).
• Estimated 1-Year Overall Survival: Reached 73% with tebentafusp compared to 59% with control therapies.
• Step-Up Dosing: Administered IV weekly: 20 mcg on Day 1, 30 mcg on Day 8, and 68 mcg on Day 15 and weekly thereafter.

Global Named-Patient Sourcing via Critical Kare Pharma

Supplied in tamper-evident manufacturer cartons accompanied by Certificates of Analysis and continuous temperature data logging.